Rodr�guez RMR, Qui�onez MA, Mart�nez SRA

Idioma: Español
Referencias bibliográficas: 23
Paginas: 198-203
Archivo PDF: 161.79 Kb.

RESUMEN

El choque s�ptico representa el tipo de choque circulatorio m�s com�n as� como la causa m�s frecuente de muerte en la Unidad de Cuidados Intensivos. Con el avance de la medicina basada en evidencia se decide ilustrar al lector en una selecci�n de art�culos que posiblemente cambien nuestra pr�ctica cl�nica con respecto al choque s�ptico. Estos art�culos fueron publicados entre 2013 y 2014. Las gu�as de manejo actuales destacan ciertos cambios como el hecho de preferencia de cristaloides sobre coloides en la fluidoterapia de resucitaci�n, la designaci�n de la norepinefrina como vasopresor de elecci�n para el choque s�ptico y el �nfasis en el manejo protocolizado cumpliendo metas en las primeras seis horas de reconocimiento del choque. A pesar de lo anterior, recientes publicaciones han virado nuestro rumbo hacia el paradigma del manejo protocolizado as� como la elecci�n del cristaloide adecuado en el manejo de estos pacientes. Se concluye que los aspectos m�s importantes en el manejo del choque s�ptico para disminuir la mortalidad son el reconocimiento temprano del choque, la administraci�n dentro de la primera hora de los antibi�ticos y la fluidoterapia adecuada de resucitaci�n.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Angus D, van der Pohl T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840-851.

2. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726-1734.

3. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311(13):1308-1316.

4. Linder A, Guh D, Boyd J, Walley K, Anis A, Russell J. Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population. Crit Care Med. 2014;42:2211-2218.

5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013;41:580-637.

6. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.

7. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-1693.

8. ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-1506.

9. Ferrer C, Loeches I, Phillips G, Osborn T, Townsend S, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749-1755.

10. Rochwerg B, Alhazzani W, Sindi A, Ansdell D, Thabane L, Robichoud A, et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med. 2014;161:347-355.

11. Kadri SS, Danner RL. ACP Journal Club: review: in sepsis, the effect of resuscitation with crystalloid and colloid fluids on mortality varies. Ann Intern Med. 2014;161(10):JC12.

12. Raghunathan K, Shaw A, Nathanson B, Sturmer T, Brookhart A, Stefan M, et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med. 2014;42:1585-1591.

13. Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med. 2013;369(13):1243-1251.

14. Waechter J, Kumar A, Lapinsky S, Marshall J, Dodek P, Arabi Y, et al. Interaction between fluids and vasoactive agents on mortality in septic shock: a multicenter, observational study. Crit Care Med. 2014;42:2158-2168.

15. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653-658.

16. Kox M, Pickkers P. �Less is more� in critically ill patients: not too intensive. JAMA Intern Med. 2013;173(14):1369-1372.

17. Funk D, Doucette S, Pisipati A, Dodek P, Marshall JC, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Low-dose corticosteroid treatment in septic shock: a propensity-matching study. Crit Care Med. 2014;42(11):2333-2341.

18. Trzeciak S, Glaspey LJ, Dellinger RP, Durflinger P, Anderson K, Dezfulian C, et al. Randomized controlled trial of inhaled nitric oxide for the treatment of microcirculatory dysfunction in patients with sepsis. Crit Care Med. 2014;42(12):2482-2492.

19. Janz DR, Bastarache JA, Rice TW, Bernard GR, Warren MA, Wickersham N, et al. Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis trial. Crit Care Med. 2015;43(3):534-541.

20. TRISS Trial Group. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371:1381-191.

21. ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412-1421.

22. SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370:1583-9153.

23. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683-1691.